Successful Phase 3 MDMA Study Opens Door for FDA Approval
Last reviewed and updated: July 5, 2026.
Key Takeaways
| Phase 3 was positive | MAPS’ Phase 3 trials showed 67-71% PTSD response rates — the clinical data was and remains compelling. |
| FDA rejected in 2024 | The FDA issued a Complete Response Letter in August 2024, rejecting MDMA-assisted therapy — not due to efficacy concerns but citing trial methodology issues. |
| Key objections | The FDA flagged functional unblinding (participants knowing they received MDMA), therapist conduct concerns, and questions about real-world abuse potential. |
| Path forward | Lykos Therapeutics (formerly MAPS PBC) is redesigning the trial to address the FDA’s methodology objections, with resubmission expected. |
| Ketamine fills gap | While MDMA awaits resubmission, ketamine (as Spravato) has become the de facto approved treatment for PTSD — a role it has taken on more formally since the 2024 rejection. |
Traditional therapy has been a tool to treat PTSD (Post-Traumatic Stress Disorder) in veterans, first responders, sexual assault victims, and more. Previous studies had found that when therapists add MDMA -– also known as ecstasy or molly -– the symptoms of PTSD were alleviated to varying degrees.
Now, a large, successful study again showed MDMA-assisted therapy alleviates PTSD symptoms like no other treatment can. The study, published in Nature Medicine, found that 71 percent of people who did MDMA-assisted therapy no longer met criteria for PTSD.
RELATED: VA Accelerates MDMA-Assisted Therapy for Veterans Amidst Escalating Suicide Crisis
The patients who did MDMA-assisted therapy saw improvements in their family, social and work life. By one measure, MDMA-assisted therapy was about twice as effective as therapy alone.
“It confirms MDMA works,” Matthias Liechti, a psychopharmacologist at the University of Basel in Switzerland, told Nature.
RELATED: Alternatives to MDMA Therapy for PTSD: Effective Treatment Options
FDA Approval May Be Next
The study opens the door for legal MDMA-assisted therapy.
The study’s sponsors, the Multidisciplinary Association for Psychedelic Studies, have been working to legalize the treatment for more than two decades. MAPS has now done two large, placebo-controlled studies showing MDMA-assisted therapy allieviates PTSD.
This second large successful study means that MAPS can now seek approval from the Food and Drug Administration to roll out MDMA-assisted psychotherapy. In 2017, the FDA called MDMA-assisted therapy a “breakthrough.” The designation means the FDA will evaluate it quickly. The FDA may give the go-ahead as soon as next year. Clinics may start using the treatment soon after.
Ready to explore a new horizon in mental health? Try out the beta version of HealingChat, HealingMaps AI chatbot that takes all our vetted content, clinics and retreats to answer all your questions in a safe environment. Try the beta version now!
A Sea Change Ahead
If the treatment is allowed, it would be a major shift in medicine and culture. There has been virtually no legal psychedelic use for four decades, except in small clinical trials like this one.
MDMA was outlawed in 1985. If approved, MDMA would move out of Schedule 1, and could be prescribed by doctors for use by therapists.
A legal psychedelic treatment would undercut the government’s view that drugs like MDMA, LSD and cannabis have no medical uses and are easy to abuse, and so shouldn’t be used by anyone for any reason.
MDMA-assisted therapy would give therapists a new, powerful tool to address hard-to-treat problems. MDMA-assisted therapy would give folks who are suffering legal access to an experience, MDMA, that can be among the most profound, gentle, loving, and opening feelings of a lifetime.
RELATED: Magic Mushrooms Offer Hope As A Potential Future Treatment for Anorexia Nervosa
Study Results in Big Improvements
PTSD is painful, and can wreck lives. The condition is so torturous that people can drop out from work, friend groups, and families. PTSD affects about 5 percent of Americans. The best therapies available now only work for about 50 percent of people.
This study found that MDMA works because it gives people a different sense of themselves. MDMA “induces prosocial feelings and softens responses to emotionally challenging and fearful stimuli,” the study found. MDMA does this by “enhancing the ability of individuals with PTSD to benefit from psychotherapy by reducing sensations of fear, threat and negative emotionality.” The study’s lead, Jennifer Mitchell, told Nature that MDMA works as a “communication lubricant,” letting people talk to their therapist about their pain with less shame or horror.
Interested in joining a Psychedelics Clinical Trial? Sign up here now and we will connect you with a clinical trial in your area when one becomes available.
How the Study Worked
Over the course of 18 weeks, about 100 people with PTSD were given six 90-minute therapy sessions. Therapists did three, 8-hour “medicine” sessions in which they gave people blindfolds and played evocative music, and people settled down on a couch with a blanket. Half of the people got MDMA–between 160 and 180 milligrams. Half got a placebo.
The participants had lived with PTSD for an average of 16 years. They were combat veterans, survivors of sexual assault and childhood trauma. Many also suffered from things like depression, suicidal thoughts or substance abuse.
At the end, the patients were evaluated by two tests measuring PTSD and disability. The patients who got MDMA improved in many ways, including using less alcohol. Females did better than males. People from all kinds of different ethnic backgrounds improved.
The results in this clinical trial were similar to those in a study published in 2021, which found that 67 percent of people who got MDMA-assisted therapy no longer qualified for PTSD.
Notably, therapy alone was also effective at treating PTSD. Nearly half of the people in this study who got a placebo no longer met criteria for PTSD.
There were few adverse events; MDMA-assisted therapy was again proved broadly safe for well-screened participants who are guided by professionals.
An Uncertain Path Ahead
The director of MAPS, Rick Doblin, told the New York Times that “it feels a bit too early to really celebrate.” There are still many hurdles before regular people can access MDMA-assisted therapy, even after FDA approval. MAPS and the FDA have to agree on the protocols. How many therapy sessions will a client have to do? What kind of training, exactly, will therapists need? Where can the sessions take place?
There still aren’t enough therapists trained in MDMA-assisted therapy. The lack of trained therapists will likely be a huge bottleneck. MAPS is coordinating with partner organizations to increase the training opportunities.
“Drug-assisted therapy hasn’t been approved before, so there’s not a lot of precedent,” Amy Emerson, chief executive of the MAPS Public Benefit Corporation, told the Times.
2026 Update
When this article was published, the Phase 3 results for MDMA-assisted therapy were cause for genuine optimism. A 67-71% PTSD response rate across MAPS’ trials was remarkable — stronger than any conventional treatment in the literature. But the FDA did not approve it. In August 2024, the agency issued a Complete Response Letter rejecting MDMA-assisted therapy — the first major psychedelic therapy rejection after years of momentum. Critically, the FDA did not dispute the efficacy data. It raised methodology concerns: functional unblinding (the impossibility of placebo-blinding a psychedelic trial), concerns about therapist conduct in some sessions, and questions about how abuse potential would manifest outside the controlled trial environment.
The rejection was a setback, not a reversal. Lykos Therapeutics (the for-profit entity formerly known as MAPS PBC) is redesigning the trial to address the FDA’s specific objections, with a resubmission expected within the next several years. Meanwhile, the landscape has shifted: ketamine — specifically Spravato (esketamine) — has expanded its role as the accessible, approved treatment for PTSD while MDMA awaits resubmission. April 2026’s Executive Order on psychedelic medicine directed the VA to study MDMA and other psychedelics for veterans, maintaining institutional momentum. The 67-71% response rate data hasn’t gone anywhere — it remains the strongest argument for MDMA’s eventual approval.
Frequently Asked Questions
- Was MDMA therapy approved by the FDA?
- No. Despite promising Phase 3 trial data showing 67-71% PTSD response rates, the FDA issued a Complete Response Letter in August 2024, rejecting MDMA-assisted therapy. The rejection cited trial methodology concerns — particularly functional unblinding and therapist conduct issues — not the efficacy data itself. Lykos Therapeutics is working to address the FDA’s concerns and plans to resubmit.
- Why did the FDA reject MDMA therapy if the trial data was so strong?
- The FDA’s main objections were methodological, not clinical. Functional unblinding — the near-impossibility of blinding participants to whether they received MDMA vs. placebo — made it difficult to control for expectancy effects. The FDA also raised concerns about therapist conduct in some trial sessions and about how potential for abuse would manifest outside the controlled environment of a clinical trial.
- What is Lykos Therapeutics doing now?
- Lykos Therapeutics (formerly MAPS PBC) is working with the FDA to redesign the trial to address the Complete Response Letter’s specific objections. This involves developing better methodologies for blinding assessment, implementing stronger therapist conduct protocols, and addressing the real-world abuse potential question. A resubmission timeline has not been publicly confirmed, but the company remains committed to the approval pathway.
- What PTSD treatments are available now while MDMA awaits resubmission?
- Spravato (esketamine) has expanded its PTSD evidence base and a label expansion is in progress. IV ketamine has an established off-label track record for PTSD. The April 2026 Executive Order directed the VA to expand access to ketamine and other psychedelic research for veterans. Psilocybin for PTSD is in active Phase 2 trials. Stanford’s 2024 Nature Medicine study showed strong ibogaine results in Special Forces veterans.
RELATED READING: What is Ketamine Therapy? | Psilocybin Therapy Guide | Psychedelic Therapy Overview
